A Rivals Clinical Stumble Sends Sarepta Therapeutics Stock Lower Sarepta Therapeutics shares react to Novartis Phase 3 trial results in DM1 while Sarepta progresses its SRP-1003 RNA therapy clinical trials.
Novartis Myotonic Dystrophy Trial Flop Sends Dyne Therapeutics Shares Tumbling Dyne Therapeutics stock sinks on Novartis' failed Phase 3 myotonic dystrophy study, even as Dyne prepares new trial data presentations.
How Novartis And Ionis' High-Profile Failure Reverberated Through Biopharma Novartis and Ionis' high-profile Lp(a) flop on Friday reverberated through biotech stocks on Tuesday.
Novartis, Ionis Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session U.S. stock futures fell as Novartis plunged 12.7% after pelacarsen’s Phase III trial missed its endpoint; other biotech stocks also declined.
Novartis Stock Drops as Trial Failures Ripple Across Biotech Partners Novartis stock falls following Phase 3 clinical trial failures for del-desiran and pelacarsen, impacting Ionis and Royalty Pharma shares.
United Natural Foods, ABM Industries and 3 Stocks to Watch Heading Into Tuesday Stocks in focus: UNFI and ABM earnings, Novartis trial miss, Co-Diagnostics CFO change, and Casey’s earnings expected.
Novartis, Ionis Tumble On Surprise Flop For Heart Drug Novartis' Ionis-partnered Lp(a) blocker failed in testing. Both stocks fell.
A Wall Street Analyst Spotted the Trial Freeze—Then Came News of Three Deaths Novartis and Bristol Myers pause CAR-T autoimmune trials after patient deaths and severe side effects spark safety concerns.
The Multiple Sclerosis Drug Race Just Got Hotter After Novartis’ Phase 3 Win Novartis stock spikes 5% on positive Phase 3 REMODEL trial results for relapsing MS drug remibrutinib with no liver safety signals.
Why Novartis Just Surged 6%, Eyeing A Breakout Novartis stock surged early Tuesday after its experimental multiple sclerosis treatment succeeded in a pair of midstage studies.
VIG, VYM, and VYMI: Which Vanguard Dividend ETF Is Right for You? Vanguard offers three dividend ETFs—VIG, VYM, and VYMI—with distinct yields, holdings, and geographic focus, giving income investors varied ways to access dividend-paying stocks.
Breakfast News: A Conversation With Ionis CEO Ionis Pharmaceuticals CEO on a major profitability milestone, breakthrough medicines and more.
Which Healthcare ETF Is the Better Buy: VanEck's Pharma PPH or State Street's Biotech XBI? PPH offers the income and stability of proven pharmaceutical leaders while XBI swings for the fences across 155 smaller biotech names.
PPH vs. IYH: Which Healthcare Fund Is the Better Buy? PPH concentrates on just 26 drugmakers, while IYH diversifies more broadly across 100 healthcare holdings.
This ETF Is Outperforming by Avoiding the S&P 500’s Biggest Problem The JPMorgan International Value ETF (JIVE) has outpaced the S&P 500 this year, offering low-volatility, diversified international exposure with a 1.22% yield and rising institutional demand.
The L.A. Lakers Delivered a 1-Year Return of 25%. These ETFs Have Done Even Better. Most people don't have $12.5 billion to buy the L.A. Lakers. But with stock ETFs, you could earn a higher return than the Lakers' owners.
Vanguard Is Bullish on Developed Markets Outside the U.S. -- But How Can You Buy Them? These 2 ETFs Can Help. Want to put your money into global stocks that might be big winners from AI? These two low-cost ETFs offer international diversification.
VanEck Pharmaceutical ETF vs. Invesco Biotech ETF: Which Fund Fits Your Investing Style? VanEck targets established pharma giants with lower costs and volatility, while Invesco pursues high-growth biotech companies. One delivered stronger returns; the other weathered downturns better.
3 Dividend Stocks to Buy for a Lifetime of Passive Income These companies' recent headwinds shouldn't lead to decreased payouts.
Concentrated Pharma Exposure or Broader Global Healthcare? PPH vs. IXJ The VanEck Pharmaceutical ETF (PPH) gives investors a concentrated way to own major drugmakers, while the iShares Global Healthcare ETF (IXJ) spreads exposure across the wider healthcare sector. The choice comes down to whether to lean into pharma-driven returns or take a broader approach to global healthcare.
Novartis (NVS) Q2 2026 Earnings Call Transcript Growth drivers offset generic erosion as priority brands surge 36% in constant currency.
Novartis Q2 Earnings Call Highlights Novartis (
NYSE:NVS ) said it returned to sales growth in the second quarter of 2026, supported by strong gains across priority medicines and launches, while reaffirming its full-year outlook despite continued pressure from U.S. generic erosion tied to Entresto.
Chief Executive Officer Vas Narasimhan
